Report 20: Using mobility to estimate the transmission intensity of COVID-19 in Italy: A subnational analysis with future scenarios
Summary
Italy was the first European country to experience sustained local transmission of COVID-19. As of 1st May 2020, the Italian health authorities reported 28,238 deaths nationally. To control the epidemic, the Italian government implemented a suite of non-pharmaceutical interventions (NPIs), including school and university closures, social distancing and full lockdown involving banning of public gatherings and non essential movement. In this report, we model the effect of NPIs on transmission using data on average mobility. We estimate that the average reproduction number (a measure of transmission intensity) is currently below one for all Italian regions, and significantly so for the majority of the regions. Despite the large number of deaths, the proportion of population that has been infected by SARS-CoV-2 (the attack rate) is far from the herd immunity threshold in all Italian regions, with the highest attack rate observed in Lombardy (13.18% [10.66%-16.70%]). Italy is set to relax the currently implemented NPIs from 4th May 2020. Given the control achieved by NPIs, we consider three scenarios for the next 8 weeks: a scenario in which mobility remains the same as during the lockdown, a scenario in which mobility returns to pre-lockdown levels by 20%, and a scenario in which mobility returns to pre-lockdown levels by 40%. The scenarios explored assume that mobility is scaled evenly across all dimensions, that behaviour stays the same as before NPIs were implemented, that no pharmaceutical interventions are introduced, and it does not include transmission reduction from contact tracing, testing and the isolation of confirmed or suspected cases. New interventions, such as enhanced testing and contact tracing are going to be introduced and will likely contribute to reductions in transmission; therefore our estimates should be viewed as pessimistic projections. We find that, in the absence of additional interventions, even a 20% return to pre-lockdown mobility could lead to a resurgence in the number of deaths far greater than experienced in the current wave in several regions. Future increases in the number of deaths will lag behind the increase in transmission intensity and so a second wave will not be immediately apparent from just monitoring of the daily number of deaths. Our results suggest that SARS-CoV-2 transmission as well as mobility should be closely monitored in the next weeks and months. To compensate for the increase in mobility that will occur due to the relaxation of the currently implemented NPIs, adherence to the recommended social distancing measures alongside enhanced community surveillance including swab testing, contact tracing and the early isolation of infections are of paramount importance to reduce the risk of resurgence in transmission.
SUGGESTED CITATION Michaela A. C. Vollmer, Swapnil Mishra, H Juliette T Unwin, Axel Gandy et al. Using mobility to estimate the transmission intensity of COVID-19 in Italy: a subnational analysis with future scenarios. Imperial College London (2020) doi:https://doi.org/10.25561/78677
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Centre funding from the UK Medical Research Council under a concordat with the UK Department for International Development, the NIHR Health Protection Research Unit in Modelling Methodology and Community Jameel.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Our model utilizes daily real-time death data provided by the Italian Civil Protection (publicly available at https://github.com/pcm-dpc/COVID-19) for the 20 Italian regions. For the Trentino Alto-Adige region, we report the results for the provinces of Trento and Bolzano separately, following the format of the death data provided by the Italian Civil Protection. For population counts, we use publicly available age-stratified counts from ISTAT (”Popolazione residente comunale per sesso anno di nascita e stato civile”, from https://www.istat.it). Mobility data have been obtained from the Google Mobility Report (google.com/covid19/mobility/) which provides data on movement in Italy by region
Subject Area
- Addiction Medicine (399)
- Allergy and Immunology (710)
- Anesthesia (201)
- Cardiovascular Medicine (2949)
- Dermatology (249)
- Emergency Medicine (440)
- Epidemiology (12754)
- Forensic Medicine (12)
- Gastroenterology (829)
- Genetic and Genomic Medicine (4588)
- Geriatric Medicine (419)
- Health Economics (729)
- Health Informatics (2921)
- Health Policy (1069)
- Hematology (389)
- HIV/AIDS (924)
- Medical Education (426)
- Medical Ethics (115)
- Nephrology (469)
- Neurology (4366)
- Nursing (236)
- Nutrition (640)
- Oncology (2273)
- Ophthalmology (647)
- Orthopedics (258)
- Otolaryngology (325)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (501)
- Pediatrics (1197)
- Primary Care Research (496)
- Public and Global Health (6947)
- Radiology and Imaging (1529)
- Respiratory Medicine (915)
- Rheumatology (438)
- Sports Medicine (385)
- Surgery (489)
- Toxicology (60)
- Transplantation (212)
- Urology (181)